Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis

Autoimmunity Reviews

Volumn 12, Issue 2, 2012, Pages 114-120

  Villalta, Danilo ^a   Imbastaro, Tiziana ^b   Di Giovanni, Sabrina ^b   Lauriti, Ciro ^c   Gabini, Marco ^c   Turi, Maria Costanza ^d   Bizzaro, Nicola ^e  

^a S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^b PO Santo Spirito   (Italy)

^c Reumatologia Dipartimento di Medicina   (Italy)

^d UNIVERSITY OF CHIETI   (Italy)

^e Ospedale S Antonio   (Italy)

Author keywords

Antinuclear autoantibodies (ANA); Antinucleolar autoantibodies (ANoA); Multiplex line immunoblot (LIA); Systemic sclerosis (SSc)

Indexed keywords

AUTOANTIBODY; CENTROMERE ANTIBODY; DNA DIRECTED RNA POLYMERASE III; DNA TOPOISOMERASE; FIBRILLARIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RECOMBINANT PROTEIN;

ADULT; AGED; ANTIBODY DETECTION; BIOCHEMISTRY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOPRECIPITATION; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMIC SCLEROSIS;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; FEMALE; HUMANS; IMMUNOBLOTTING; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SCLERODERMA, SYSTEMIC; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84870250506     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.07.005     Document Type: Review

References (61)

1. Denton C.P., Black C.M. Scleroderma - clinical and pathological advances. Best Pract Res Clin Rheumatol 2004, 18:271-290.
2. Chighizola C., Shoenfeld Y., Meroni P.L. Systemic sclerosis. Introduction. Autoimmun Rev 2011, 10:239-240.
3. Chizzolini C., Brembilla N.C., Montanari E., Truchetet M.E. Fibrosis and immune dysregulation in systemic sclerosis. Autoimmun Rev 2011, 10:276-281.
4. Dieudé P., Boileau C., Allanore Y. Immunogenetics of systemic sclerosis. Autoimmun Rev 2011, 10:282-290.
5. Wei J., Bhattacharyya S., Tourtellotte W.G., Varga J. Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy. Autoimmun Rev 2011, 10:267-275.
6. Cipriani P., Marrelli A., Liakouli V., Di Benedetto P., Giacomelli R. Cellular players in angiogenesis during the course of systemic sclerosis. Autoimmun Rev 2011, 10:641-646.
7. Fenoglio D., Bernuzzi F., Battaglia F., Parodi A., Kalli F., Negrini S., et al. Th17 and regulatory T lymphocytes in primary biliary cirrhosis and systemic sclerosis as models of autoimmune fibrotic diseases. Autoimmun Rev May 23 2012, [Epub ahead of print].
8. Tan E.M., Rodnan G.P., Garcia I., Moroi Y., Fritzler M.J., Peebles C. Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 1980, 23:617-625.
9. Bryan C., Knight C., Black C.M., Silman A.J. Prediction of five years survival following presentation with scleroderma: development of a simple model using three factors at first visit. Arthritis Rheum 1999, 42:2660-2665.
10. Koening M., Dieude M., Senecal J.L. Predictive value of antinuclear autoantibodies: the lesson of the systemic sclerosis autoantibodies. Autoimmun Rev 2008, 7:588-593.
11. Bizzaro N., Tonutti E., Villalta D., Bassetti D., Tozzoli R., Manoni F., et al. Sensitivity and specificity of immunological methods for the detection of anti-topoisomerase I (Scl70) autoantibodies: results of a multicenter study. Clin Chem 2000, 46:1681-1685.
12. Fritzler M.J., Rattner J.B., Luft L.M., Edworthy S.M., Casiano C.A., Peebles C., Mahler M. Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F. Autoimmun Rev 2011, 10:194-200.
13. Czömpöly T., Simon D., Czirják L., Németh P. Anti-topoisomerase I autoantibodies in systemic sclerosis. Autoimmun Rev 2009, 8:692-696.
14. Tormey V.J., Bunn C.C., Denton C.P., Black C.M. Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology 2001, 40:1157-1162.
15. Mahler M., Raijmakers R. Novel aspect of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmun Rev 2007, 6:432-437.
16. Reddy R., Tan E.M., Henning D., Nohga K., Busch H. Detection of a nucleolar 7-2 ribonucleoprotein and a cytoplasmic 8-2 ribonucleoprotein with autoantibodies from patients with scleroderma. J Biol Chem 1983, 258:1383-1386.
17. Chan E.K.L., Imai H., Hamel J.C., Tan E.M. Human autoantibody to RNA polymerase I transcription factor hUBF. Molecular identity of nucleolus organizer region autoantigen NOR and ribosomal transcription upstream binding factor. J Exp Med 1991, 174:1239-1244.
18. Tozzoli R., Villalta D. Anti-RNA polymerase III autoantibodies. Autoantibodies 2007, 247-254. Elsevier, Amsterdam. 2nd ed. Y. Shoenfed, M.E. Gershwin, P.L. Meroni (Eds.).
19. Mimori T., Akizuki M., Yamagata H., Inada S., Yoshida S., Homma M. Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis-scleroderma overlap. J Clin Invest 1981, 68:611-620.
20. Baroni S.S., Santillo M., Bevilacqua F., Luchetti M., Spadoni T., Mancini M., et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006, 354:2667-2676.
21. Gabrielli A., Svegliati S., Moroncini G., Luchetti M., Tonnini C., Avvedimento E.V. Stimulatory autoantibodies to the PDGF receptor: a link to fibrosis in scleroderma and pathway for novel therapeutic targets. Autoimmun Rev 2007, 7:121-126.
22. Kuwana M., Okano Y., Pandey J.P., Silver R.M., Fertig N., Medsger T.A. Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical association in systemic sclerosis. Arthritis Rheum 2005, 52:2425-2432.
23. Mahler M., Fritzler M.J. PM1-alpha ELISA: the assay of choice from the detection of anti-PM/Scl autoantibodies?. Autoimmun Rev 2009, 8:373-378.
24. Villalta D., Morozzi G., Tampoia M., Alpini C., Brusca I., Salgarolo V., et al. Antibodies to fibrillarin, PM-Scl and RNA polymerase III detected by ELISA assays in patients with systemic sclerosis. Clin Chim Acta 2010, 411:710-713.
25. Masi A.T., Rodnan G.P., Medsger T.A., Altman R.D., D'Angelo W.A., Fries J.F. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581-590.
26. LeRoy E.C., Black C.M., Fleischmajer R., Jablonska S., Krieg T., Medsger T.A., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
27. Reveille J.D., Solomon D.H. Evidence-based guidelines for the use of immunological tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 2003, 49:399-412. and the American College of Rheumatology ad Hoc Committee on Immunological Testing Guidelines.
28. Nihtyanova S.I., Denton C.P. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 2010, 6:112-116.
29. Jaskowski T.D., Wilson A., Hill H.R., Tebo A.E. Diagnostic assays for anti-PM/Scl IgG antibodies: heterogeneity in antibody response or lack of standardization?. Clin Chim Acta 2011, 412:1100-1105.
30. Jaeschke R., Guyatt G., Sackett D.L., for the Evidence-Based Medicine Working Group Users' guide to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid?. JAMA 1994, 271:389-391.
31. Jaeschke R., Guyatt G., Sackett D.L., for the Evidence-Based Medicine Working Group Users' guide to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients?. JAMA 1994, 271:703-707.
32. Mahler M., Maes L., Blockmans D., Westhovens R., Bossuyt X., Riemekasten G., et al. Clinical and serological evaluation of a novel CENP-A peptide based ELISA. Arthritis Res Ther 2010, 12:R99.
33. Mahler M., Silverman E.D., Schulte-Pelkum J., Fritzler M.J. Anti-Scl-70 (topo-I) antibodies in SLE: myth or reality?. Autoimmun Rev 2010, 9:756-760.
34. Steen V.D., Powell D.L., Medsger T.A. Clinical correlation and prognosis based on serum autoantibodies in patient with progressive systemic sclerosis. Arthritis Rheum 1988, 31:196-203.
35. Bernstein R.M., Steigerwald J.C., Tan E.M. Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis. Clin Exp Immunol 1982, 48:43-51.
36. Ho K.T., Reveille J.D. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 2003, 5:80-93.
37. Cavazzana I., Angela C., Paolo A., Stefania Z., Angela T., Franco F. Anti-RNA polymerase III antibodies. A marker of systemic sclerosis with rapid onset and skin thickening progression. Autoimmun Rev 2009, 8:580-584.
38. Dagher J.H., Scheer U., Voit R., Grummt I., Lonzetti Y.R., Senecal J.L. Autoantibodies to NOR 90/hUBF: longterm clinical and serological followup in a patient with limited systemic sclerosis suggests an antigen driven immune response. J Rheumatol 2002, 29:1543-1547.
39. Hanke K., Brückner C.S., Dähnrich C., Huscher D., Komorowski L., Meyer W., et al. Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients. Arthritis Res Ther 2009, 11:R22.
40. Bidoli E., Villalta D. Epidemiological and ethical aspect of multiplex autoantibody testing. Autoimmun Rev 2007, 6:354-358.
41. Meyer O.C., Fertig N., Lucas N., Somogyi N., Medsger T.A. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 2007, 34:104-109.
42. Bardoni A., Rossi P., Salvini R., Bobbio-Pallavicini F., Caporali R., Montecucco C. Autoantibodies to RNA-polymerases in Italian patients with systemic sclerosis. Clin Exp Rheumatol 2003, 21:301-306.
43. Morozzi G., Bellisai F., Fineschi I., Scaccia F., Pucci G., Simpatico A., et al. Prevalence of anti-histone antibodies, their clinical significance and correlation with other autoantibodies in a cohort of Italian scleroderma patients. Autoimmun Highlights 2011, 2:29-33.
44. Codullo V., Morozzi G., Bardoni R., Salvini G., Deleonardi G., De Pità O., et al. Validation of a new immunoenzymatic method to detect antibodies to RNA polymerases III in systemic sclerosis. Clin Exp Rheumatol 2007, 25:373-377.
45. Alderuccio F., Chan E.K., Tan E.M. Molecular characterization of an autoantigen of PM-Scl in the polymyositis/scleroderma overlap syndrome: a unique and complete human cDNA encoding an apparent 75-kD acid protein of the nucleolar complex. J Exp Med 1991, 173:941-952.
46. Blütner M., Bautz F.A. Cloning and characterization of the cDNA coding for a polymyositis-scleroderma overlap syndrome related nucleolar 100-kD protein. J Exp Med 1992, 176:973-980.
47. Raijmakers R., Renz M., Wiemann C., Egberts W.V., Seeling H.P., van Venrooij W.J., et al. PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome. Arthritis Rheum 2004, 50:565-569.
48. Aggarwal R., Lucas M., Fertig N., Oddis V., Medsger T.A. Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum 2009, 60:1112-1118.
49. Sharif R., Fritzler M.J., Mayes M.D., Gonzales E.B., McNearney T.A., Draeger H., et al. Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysis. J Rheumatol 2011, 38:1622-1630.
50. Gold H.A., Topper J.N., Clayton D.A., Craft J. The RNA processing enzyme RNase MRP is identical to the Th RNP and related to RNase P. Science 1989, 245:1377-1380.
51. Jacobsen S., Ullman S., Shen G.Q., Wiik A., Halberg P. Influence of clinical features, serum antinuclear antibodies, and lung functions on survival of patients with systemic sclerosis. J Rheumatol 2001, 28:2454-2459.
52. Ceribelli A., Cavazzana I., Franceschini F., Airò P., Tincani A., Cattaneo R., et al. Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma. J Rheumatol 2010, 37:2071-2075.
53. Gliddon A.E., Dorè C.J., Dunphy J., Betteridge Z., McHugh N.J., Maddison P.J. Antinuclear antibodies and clinical associations in a British Cohort with limited cutaneous systemic sclerosis. J Rheumatol 2011, 38:702-705. and the QUINS Trial Study Group.
54. Belizna C., Henrion D., Beucher A., Lavigne C., Ghaali A., Levesque H. Anti-Ku: clinical, genetic and diagnostic insights. Autoimmun Rev 2010, 9:691-694.
55. Rozman B., Cucnik S., Sodin-Semrl S., Czirjak L., Varjú C., Distler O., et al. Prevalence and clinical association of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case-control study. Ann Rheum Dis 2008, 67:1282-1286.
56. Dagher J.H., Scheer U., Voit R., Grummt J., Lonzetti L., Raymond Y., Senecal J.L. Autoantibodies to NOR 90/hUBF: longterm clinical and serological followup in a patient with limited systemic sclerosis suggests an antigen driven immune response. J Rheumatol 2002, 29:1543-1547.
57. Andrae J., Gallini R., Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008, 22:1276-1312.
58. Classen J.F., Henrohn D., Rorsman F., Lennartsson J., Lauwerys B.R., Wikström G., et al. Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum 2009, 60:1137-1144.
59. Loizos N., Lariccia L., Weiner J., Griffith H., Boin F., Hummers L., et al. Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera. Arthritis Rheum 2009, 60:1145-1151.
60. Balada E., Simeon-Aznar C.P., Ordi-Ros J., Rosa-Leyva M., Selva-O'Callaghan A., Pardos-Gea J., et al. Anti-PDGFR-alpha antibodies measured by non-bioactivity assays are not specific for systemic sclerosis. Ann Rheum Dis 2008, 67:1027-1029.
61. Kurasawa K., Arai S., Owasa T., Maezawa R., Kumano K., Fukuda T. Autoantibodies against platelet-derived growth factor receptor alpha in patients with systemic lupus erythematosus. Mol Rheumatol 2010, 20:458-465.